Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the EU / 2025-524230-25-00
Authorised, not yet recruiting Phase II

HOVON 168: Epcoritamab in Addition to R-Mini-CHOP Compared to R-Mini-CHOP in Elderly, Frail or Unfit Patients with Diffuse Large B-cell Lymphoma

2025-524230-25-00 · tracked via the Priya Life Science EU tracker
Sponsor
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Sponsor type
Patient organisation/association
Therapeutic area
Hemic and Lymphatic Diseases
Decision date
31/08/2026
Enrollment target
276
Sites
Czechia, Denmark, Croatia, Spain, Sweden, Finland, Portugal, Ireland, Netherlands, Belgium, Norway

Condition studied

Diffuse large B-cell lymphoma (DLBCL)

Investigational medicinal product(s)

MabThera 100 mg concentrate for solution for infusionEpcoritamab (GEN3013)MabThera 500 mg concentrate for solution for infusionMabThera 1400 mg solution for subcutaneous injection

Every trial of Epcoritamab and Rituximab across our registers →

Eligibility

Age group
65+ years
Sex
Female, Male

Primary endpoint

The dual primary endpoints are: 1. Complete remission (CR) on or after the End of Treatment (EOT) and 2. • PFS, defined as the duration from the date of randomization to the date of disease progression or death

Endpoint detail

Overall survical, MRD negativity, Best overall response, Complete Response, Duration of CR and BOR, Changes in PRO, Duration of MRD negativity, Safety data using descriptive statistics

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-524230-25-00 on CTIS ↗ ← All trials in the EU